http://www.expresspharmaonline.com/...tes-results-in-less-hypoglycaemia-the-lancet
According to a report published in The Lancet, a new drug could offer significant advantages over existing treatments for type II diabetes patients who don’t respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke.
“Besides [glucose regulation], other outcomes are important to patients with diabetes, such as ease of administration, weight change, and incidence of hypoglycaemia, which can all affect quality of life. The much lower risk of hypoglycaemia associated with gliptins compared with sulphonylureas might be seen as a major advantage in some patients exposed to this complication, and could affect the choice of drug to be added as second-line treatment to metformin.”
fyi
http://medicalxpress.com/news/2012-06-linagliptin-noninferior-glimepiride-diabetes.html
http://eon.businesswire.com/news/eon/20120628005391/en http://en.wikipedia.org/wiki/Linagliptin
According to a report published in The Lancet, a new drug could offer significant advantages over existing treatments for type II diabetes patients who don’t respond to metformin, the most commonly prescribed initial drug treatment for the disease. The new drug, linagliptin, results in significantly less weight gain than the most common second-line treatments currently used, and may even carry a smaller risk of cardiovascular events such as heart attack and stroke.
“Besides [glucose regulation], other outcomes are important to patients with diabetes, such as ease of administration, weight change, and incidence of hypoglycaemia, which can all affect quality of life. The much lower risk of hypoglycaemia associated with gliptins compared with sulphonylureas might be seen as a major advantage in some patients exposed to this complication, and could affect the choice of drug to be added as second-line treatment to metformin.”
fyi
http://medicalxpress.com/news/2012-06-linagliptin-noninferior-glimepiride-diabetes.html
http://eon.businesswire.com/news/eon/20120628005391/en http://en.wikipedia.org/wiki/Linagliptin
